HD-OPM Archive
Topics › PCSK9, ezetimibe & newer drugs

Oral PCSK9 inhibitor enlicitide cut LDL 58% in familial hypercholesterolemia

Louis Nervegna · Dec 01, 2025 · ♥ 12 reactions · 0 comments · original Facebook post
PCSK9, ezetimibe & newer drugsLDL, ApoB & lipid panel
AI summary & key facts

A phase 3 trial of the once-daily pill enlicitide in 303 adults with heterozygous familial hypercholesterolemia and LDL still high on statins showed large LDL reductions versus placebo. An oral option could help people reluctant to self-inject.

#pcsk9HD

Research cited

🫀 A once-daily pill may soon offer statin-resistant patients an injectable-level weapon against “bad” cholesterol.

An international phase 3 trial tested enlicitide, an oral PCSK9 inhibitor, in 303 adults with heterozygous familial hypercholesterolemia whose LDL levels remained high despite statins. Participants from 59 sites in 17 countries were randomized to enlicitide or placebo for 52 weeks, all on background statin therapy. Unlike existing PCSK9 drugs given by injection, enlicitide is taken as a tablet, a format clinicians say could improve adherence in people reluctant to self-inject.​

After 24 weeks, enlicitide cut LDL cholesterol by an average of 58.2%, while LDL rose by 2.6% in the placebo group; at 52 weeks, LDL remained 55.3% lower with enlicitide versus an 8.7% increase on placebo. The drug also reduced non-HDL cholesterol by about 52%, apolipoprotein B by roughly 48%, and lipoprotein(a) by nearly 25%, all markers tied to cardiovascular risk. Safety was broadly similar to placebo, with low discontinuation rates and no new major safety signals in the phase 3 program.​

Experts note that larger, longer outcomes trials are still needed to confirm whether these LDL reductions translate into fewer heart attacks and strokes, and to test the pill in people beyond those with familial hypercholesterolemia. Still, because enlicitide matches injectable PCSK9 inhibitors in LDL lowering while offering oral convenience, cardiologists and dietitians see it as a potentially transformative option for patients who cannot reach guideline targets with statins and lifestyle alone.​

Follow Science Sphere for regular scientific updates

📄 RESEARCH PAPER

📌 Ann Marie Navar et al, “Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia,” JAMA (2025)

No photo description available.
#statins#cholesterol#nonhdl#heartattack#cardiovascular#stroke#guidelines#jama
← newer: ESC scientific statement: diet is a primary factor in CVD prolder: Oral semaglutide did not slow Alzheimer's progression in EVO →